Ultragenyx Pharmaceutical (RARE) Interest & Investment Income (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) reported Interest & Investment Income of $6.0 million for Q1 2026, down 14.29% year-over-year from $7.0 million in Q1 2025, and down 7.86% quarter-over-quarter from $6.5 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Interest & Investment Income (2013 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has 14 years of Interest & Investment Income data on file, last reported at $6.0 million in Q1 2026.
- Interest & Investment Income for Q1 2026 came in at $6.0 million, down 14.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $24.2 million (down 31.29% YoY), and the FY2025 annual result was $25.0 million, down 32.43% from the prior year.
- Interest & Investment Income declined to $6.0 million in Q1 2026 per RARE's latest filing, from $6.5 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $10.7 million in Q3 2024 and troughed at $494000.0 in Q1 2022.
- A 5-year average of $6.2 million and a median of $6.2 million in 2022 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2022 and 2025: Interest & Investment Income jumped 1308.64% in 2022, then tumbled 45.36% in 2025.
- A 5-year view of Interest & Investment Income shows it stood at $6.2 million in 2022, then surged by 43.03% to $8.9 million in 2023, then rose by 13.3% to $10.0 million in 2024, then tumbled by 35.17% to $6.5 million in 2025, then retreated by 7.86% to $6.0 million in 2026.
- Business Quant data shows RARE's Interest & Investment Income at $6.0 million in Q1 2026, $6.5 million in Q4 2025, and $5.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 597,319.59 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 305,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -14.79 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.77 Bn | 2.36 Bn | 106.00 Mn | 6.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.00 Mn |
| Dec 31, 2025 | 6.51 Mn |
| Sep 30, 2025 | 5.86 Mn |
| Jun 30, 2025 | 5.79 Mn |
| Mar 31, 2025 | 7.00 Mn |
| Dec 31, 2024 | 10.04 Mn |
| Sep 30, 2024 | 10.73 Mn |
| Jun 30, 2024 | 7.40 Mn |
| Mar 31, 2024 | 8.82 Mn |
| Dec 31, 2023 | 8.87 Mn |
| Sep 30, 2023 | 5.88 Mn |
| Jun 30, 2023 | 5.96 Mn |
| Mar 31, 2023 | 6.29 Mn |
| Dec 31, 2022 | 6.20 Mn |
| Sep 30, 2022 | 3.48 Mn |
| Jun 30, 2022 | 899,000.00 |
| Mar 31, 2022 | 494,000.00 |
| Dec 31, 2021 | 440,000.00 |
| Sep 30, 2021 | 408,000.00 |
| Jun 30, 2021 | 441,000.00 |